High-signal headlines only - macro events, earnings, M&A, regulatory. Listicles and analyst clickbait filtered out by default. Refreshed hourly.
Pfizer Inc (NYSE:PFE, XETRA:PFE) beat Wall Street expectations for its second-quarter 2026 results and raised the midpoint of its full-year revenue guidance, as growth from launched and acquired products helped offset declines in its COVID-19 portfolio. The pharmaceutical company reported...
While the top- and bottom-line numbers for Pfizer (PFE) give a sense of how the business performed in the quarter ended June 2026, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Pfizer faces $17 billion patent cliff as investors brace for earnings
Pfizer (PFE) delivered earnings and revenue surprises of +13.24% and +4.04%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
The drugmaker posted adjusted earnings of 77 cents per share and now expects full-year revenue of $60.5 billion to $62.5 billion
Today Earnings (a.m.): Merck, Pfizer, McDonald's, Caterpillar, Spotify, Apollo, TPG, Marathon Petroleum, Archer-Daniels-Midland, DuPont, Kimberly-Clark Earnings (p.m.): SpaceX, Advanced Micro Devices, ...
Earnings continue to be the market's engine, and a series of results this week from Palantir, SpaceX, and AMD are set to rev up stocks again.
Global pharmaceutical company Pfizer (NYSE:PFE) will be reporting earnings this Tuesday before market hours. Here’s what to expect.
Markets enter an earnings-dominated week with a huge concentration of corporate results spanning technology, industrials, healthcare, consumer discretionary, and entertainment sectors. This will provide a critical assessment of economic health and corporate fundamentals amid persistent uncertainty about technology sector valuations and AI infrastructure spending.
There is more to this stock than meets the eye.
Amgen heads into Q2 earnings with a history of beats as investors watch key drug sales trends and seek updates on its MariTide obesity candidate.
The RNA-focused biotech shed 30% of its market value — or close to $12 billion — amid growing investor concerns about its main drug business.
Beyond analysts' top-and-bottom-line estimates for Pfizer (PFE), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended June 2026.
Strong sales of blood thinner Eliquis and newer drugs Camzyos and Reblozyl pushed second-quarter revenue to $12.97 billion, above analyst estimates
Bristol Myers Squibb faces declining revenue in its legacy drug portfolio, but new products like Opdivo are offsetting the drop.
MRNA is likely to face a key Q2 test as investors await results, FDA updates on mRNA-1010 and commercialization plans that could shape its post-COVID growth.
Pfizer heads into Q2 earnings with expectations for growth in key products, COVID headwinds, and guidance updates that could shape its outlook.
Lilly (LLY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Eli Lilly's expanding oncology and newer medicine portfolio is set to play a pivotal role in its Q2 earnings alongside its blockbuster GLP-1 franchise.
Pfizer (PFE) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
OPKO Health Inc (OPK) reports significant revenue growth in pharmaceuticals and a notable reduction in net loss, despite challenges in diagnostics.
BMY heads into Q2 earnings with growth drugs driving momentum as legacy products decline, setting the stage for a closely watched earnings report.
VRTX heads into its Q2 earnings release with Trikafta, Alyftrek, Casgevy and Journavx in focus as investors watch product sales and updates on ongoing pipeline studies.
BIIB heads into Q2 results with new launches expected to offset weaker MS drug sales as investors watch Leqembi trends and the Apellis deal impact.
Pfizer's non-oncology portfolio faced mixed Q2 trends. Eliquis and Vyndaqel sales may have risen while COVID products will have declined.
Pfizer is set to announce its second-quarter earnings next month, and Wall Street expects a double-digit decline in its profit.
Pfizer (PFE) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Pfizer shares fall after CFO Dave Denton announces his exit, though the company reaffirms 2026 guidance and maintains its strategic outlook.
We use Google Analytics to count anonymous page views and understand which content gets read. No ads, no profiles. Decline keeps you on cookieless mode. Details.
